Shanghai Henlius Biotech and Intas Pharmaceuticals Ink New Licensing Deal for PD-1 mAb
China’s Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new licensing agreement with India-based...
2023
GSK’s ViiV Healthcare Secures NMPA Approval for Vocabria in HIV-1 Treatment
UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that its HIV joint venture, ViiV...
AbbVie’s Rinvoq Gains Two New Indications in China: AxSpA and Ankylosing Spondylitis
US-based pharmaceutical company AbbVie (NYSE: ABBV) has announced the receipt of two additional indication approvals...
Takeda’s Global Revenues Grow: Strong Performance in Plasma Therapies and Gastroenterology
Japan-based pharmaceutical giant Takeda (TYO: 4502) has released its financial results for the 6-month period...
BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 3% year-on-year (YOY) revenue decline, excluding foreign...
Eli Lilly’s Omvoh Receives FDA Approval for Ulcerative Colitis Treatment
The US Food and Drug Administration (FDA) has granted regulatory approval to Eli Lilly (NYSE:...
Merck Reports 9% Global Sales Growth in Q3 2023, Boosted by Keytruda and Gardasil
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has reported a robust 9%...
Strategic Alliance Formed by uBriGene, Fraserna, and Virogin for Cell and Gene Therapy Services
In a significant move to bolster the cell and gene therapy (CGT) sector, China-based biotechnology...
Fujian Cosunter Gains Ethical Approval for Phase IIa Study of GST-HG131 in Hepatitis B
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of ethical approval...
Abbisko Therapeutics Gets NMPA Approval for Phase I Study of ABSK112 in NSCLC
Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
NMPA Unveils 73rd Batch of Reference Drugs for Generic Quality Consistency
China’s National Medical Products Administration (NMPA) has released the 73rd batch of reference drugs as...
Biogen’s BIIB080 Shows Promise in Phase Ib Trial for Mild Alzheimer’s Disease
Biogen (NASDAQ: BIIB) has released preliminary findings from a Phase Ib trial for BIIB080, a...
Sinotau Pharmaceutical Group Secures Rights to Blue Earth Diagnostics’ Flotufolastat in China
Sinotau Pharmaceutical Group, a Beijing-based nuclear medicine enterprise, has entered into a licensing agreement with...
Shanghai Pharmaceuticals Partners with Asymchem for Advanced Drug Development and Production
China-based pharmaceutical distribution giant Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a...
Sonosemi Medical Secures Over USD 27.3 Million in Series B Funding for Vascular Intervention Devices
Sonosemi Medical Co., Ltd., a Shenzhen-based innovator in vascular graft intervention devices, has reportedly secured...
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
MSD Halts Phase II Trials for Glutamate Modulator MK-1942 in Alzheimer’s and Depression
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of two Phase II...
Novartis’ Pluvicto Demonstrates Positive Phase III Results in mCRPC Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released encouraging data from a Phase III study...
Life Molecular Imaging and Sinotau Pharmaceutical Secure NMPA Approval for Neuraceq in China
Germany-headquartered Life Molecular Imaging (LMI) and China-based Sinotau Pharmaceutical Group have announced that Neuraceq (florbetaben...
Innovent Biologics’ GFH925 on Track for Priority Review Status for NSCLC Treatment
The Center for Drug Evaluation (CDE) has indicated that Innovent Biologics’s (HKG: 1801) Category 1...